ATE116335T1 - Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2). - Google Patents

Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).

Info

Publication number: ATE116335T1
Authority: AT; Austria
Prior art keywords: growth factor; igf; acid residue; insulin; pct
Prior art date: 1987-12-24

Application number

AT89900786T

Other languages

English (en)

Inventor

Francis John Ballard

John Campbell Wallace

Julian Richard Este Wells

Original Assignee

Gropep Pty Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-12-24

Filing date

1988-12-20

Publication date

1995-01-15

1988-12-20 Application filed by Gropep Pty Ltd filed Critical Gropep Pty Ltd

1995-01-15 Application granted granted Critical

1995-01-15 Publication of ATE116335T1 publication Critical patent/ATE116335T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 title abstract 3
102100037852 Insulin-like growth factor I Human genes 0.000 title abstract 3
102000048143 Insulin-Like Growth Factor II Human genes 0.000 title 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 title 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 abstract 4
239000003102 growth factor Substances 0.000 abstract 2
101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 abstract 1
102100025947 Insulin-like growth factor II Human genes 0.000 abstract 1
125000000539 amino acid group Chemical group 0.000 abstract 1
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT89900786T 1987-12-24 1988-12-20 Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2). ATE116335T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
AUPI606887		1987-12-24

Publications (1)

Publication Number	Publication Date
ATE116335T1 true ATE116335T1 (de)	1995-01-15

Family

ID=3772677

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT89900786T ATE116335T1 (de)	1987-12-24	1988-12-20	Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).

Country Status (7)

Country	Link
US (1)	US5164370A (de)
EP (1)	EP0346429B1 (de)
JP (1)	JP2507106B2 (de)
AT (1)	ATE116335T1 (de)
CA (1)	CA1341204C (de)
DE (1)	DE3852636T2 (de)
WO (1)	WO1989005822A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5470828A (en) *	1987-12-24	1995-11-28	Gropep Pty. Ltd.	Peptide analogs of insulin-like growth factor II
US5652214A (en) *	1989-06-05	1997-07-29	Cephalon, Inc.	Treating disorders by application of insulin-like growth factors and analogs
US6723699B1 (en)	1989-06-05	2004-04-20	Cephalon, Inc.	Treating disorders by application of insulin-like growth factors and analogs
US6693076B1 (en)	1989-06-05	2004-02-17	Cephalon, Inc.	Treating disorders by application of insulin-like growth factors and analogs
WO1990015142A1 (en) *	1989-06-09	1990-12-13	Gropep Pty. Ltd.	Growth hormone fusion proteins
US5045531A (en) *	1989-12-18	1991-09-03	Magainin Sciences Inc.	Wound treatment employing biologically active ion channel forming peptides and proteins
US5679771A (en) *	1990-02-13	1997-10-21	Gropep Pty. Ltd.	Method for treating intestinal diseases
DE69129267T2 (de) *	1990-02-13	1998-09-10	Gropep Pty. Ltd., Adelaide	Methode zur behandlung intestinaler krankheiten
US5681814A (en) *	1990-06-07	1997-10-28	Genentech, Inc.	Formulated IGF-I Composition
SE9002732D0 (sv) *	1990-08-24	1990-08-24	Kabivitrum Ab	Product containing growth factor
SE9002731D0 (sv) *	1990-08-24	1990-08-24	Kabivitrum Ab	Product comprising growth factor
US5744139A (en) *	1991-06-28	1998-04-28	University Of Tennessee Research Corporation	Insulin-like growth factor I (IGF-1) induced improvement of depressed T4/T8 ratios
US5202119A (en) *	1991-06-28	1993-04-13	Genentech, Inc.	Method of stimulating immune response
AU2368892A (en) *	1991-07-29	1993-03-02	British Bio-Technology Limited	Igf-ii analogues
CA2120626C (en) *	1991-10-07	2009-10-06	Douglas Wilmore	Method for enhancing gut absorption
US6310040B1 (en)	1991-11-08	2001-10-30	Cephalon, Inc.	Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
WO1993023067A1 (en) *	1992-05-08	1993-11-25	Thomas Jefferson University	Igf-1 analogs
NZ260309A (en) *	1992-06-08	1997-07-27	Pharmacia Ab Substituted For K	Use of 1gf-2 for prevention or treatment of nutritional or gastrointestinal disorders and promoting neonatal growth
JPH06510065A (ja) *	1992-06-08	1994-11-10	カイロン　コーポレーション	成長因子ｉｇｆ−ｉおよび／またはｉｇｆ−ｉｉの用法
HU217543B (hu) *	1992-06-12	2000-02-28	Albert Einstein College Of Medicine Of Yeshiva University	Eljárás perifériás neuropátia kezelésére és megelőzésére alkalmas gyógyászati készítmények előállítására, valamint inzulinszerű növekedési faktor I-et és kemoterápiás szert tartalmazó gyógyászati készítmények
US5420112A (en) *	1992-06-12	1995-05-30	Lewis; Michael E.	Prevention and treatment of peripheral neuropathy
US5444045A (en) *	1992-09-17	1995-08-22	Gropep, Pty. Ltd.	Method of administering IGF-1, IGF-2, and analogs thereof to birds
GB9310049D0 (en) *	1993-05-12	1993-06-30	Cancer Res Campaign Tech	Growth factor effects
DE69434403T2 (de) *	1993-09-20	2006-05-04	Celtrix Pharmaceuticals, Inc.	Behandlung von immunologischen und hämatologischen Störungen mit IGFBP allein oder als Komplex mit IGF
WO1998011913A1 (en) *	1996-09-16	1998-03-26	Dalhousie University	Use of igf-i for the treatment of polycystic kidney disease and related indications
US6156728A (en) *	1996-11-01	2000-12-05	Genentech, Inc.	Treatment of inner ear hair cells
US6121416A (en)	1997-04-04	2000-09-19	Genentech, Inc.	Insulin-like growth factor agonist molecules
US6420518B1 (en)	1997-04-04	2002-07-16	Genetech, Inc.	Insulin-like growth factor agonist molecules
US6358916B1 (en)	1998-07-22	2002-03-19	Thomas T. Chen	Biological activity of IGF-I E domain peptide
US7118752B2 (en)	1998-07-22	2006-10-10	University Of Connecticut	Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I
US7700353B2 (en)	1998-07-22	2010-04-20	E-P Therapeutics, Inc.	Compositions and methods for inducing apoptosis in tumor cells
EP1506972A1 (de) *	1999-01-06	2005-02-16	Genentech Inc.	Mutierte Varianten des Insulin-ähnlichen Wachstumsfaktor-I (IGF-I)
AU762351B2 (en) *	1999-01-06	2003-06-26	Genentech Inc.	Insulin-like growth factor (IGF) I mutant variants
JP2002535967A (ja) *	1999-01-06	2002-10-29	ジェネンテック・インコーポレーテッド	インシュリン様成長因子（ｉｇｆ）ｉ変異体
AU763039B2 (en) *	1999-04-08	2003-07-10	Genentech Inc.	Composition based on oppositely-charged polypeptides
ATE389416T1 (de) *	2000-05-16	2008-04-15	Genentech Inc	Behandlung von knorpelerkrankungen
CN100439397C (zh) *	2001-02-09	2008-12-03	基因技术股份有限公司	Igf-1的结晶
WO2002072780A2 (en) *	2001-03-14	2002-09-19	Genentech, Inc.	Igf antagonist peptides
US7714020B2 (en)	2001-05-24	2010-05-11	Neuren Pharmaceuticals Limited	Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
EP1401808B1 (de)	2001-05-24	2009-07-08	Neuren Pharmaceuticals Limited	Gpe-analoga und peptidomimetika
US7605177B2 (en)	2001-05-24	2009-10-20	Neuren Pharmaceuticals Limited	Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
AU2002363322A1 (en) *	2001-10-26	2003-05-19	Large Scale Biology Corporation	Endothelial cell derived hemotopoietic growth factor
US7439063B2 (en) *	2002-06-11	2008-10-21	Burnham Institute For Medical Research	Neuroprotective synergy of erythropoietin and insulin-like growth factors
EP2274978B1 (de)	2003-09-12	2015-05-20	Tercica, Inc.	Verfahren zur Behandlung von IGF-1 (insulin-like growth factor 1)-Mangel
US7355018B2 (en) *	2003-09-30	2008-04-08	Regeneron Pharmaceuticals, Inc.	Modified IGF1 polypeptides with increased stability and potency
US7192738B2 (en) *	2003-10-03	2007-03-20	Genentech, Inc.	IGF binding proteins
EP1674113A1 (de) *	2004-12-22	2006-06-28	F. Hoffmann-La Roche Ag	Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol)
EP1841443A4 (de) *	2005-01-11	2012-05-02	Heart Failure Technologies Inc	Verfahren und system zur behandlung von herzfehlern
TWI406870B (zh) *	2005-02-21	2013-09-01	Chugai Pharmaceutical Co Ltd	A method of making a protein using hamster IGF-1
KR101459789B1 (ko)	2006-06-09	2014-11-07	노파르티스 아게	안정화된 인슐린-유사 성장 인자 폴리펩티드
US20120093775A1 (en)	2009-03-27	2012-04-19	Proyecto De Biomedicina Cima, S.L.	Methods and compositions for the treatment of cirrhosis and liver fibrosis
EP3344758B1 (de)	2015-09-01	2021-09-29	Ncardia B.V.	In-vitro-verfahren zur differenzierung einer menschlichen pluripotenten stammzellpopulation in eine kardiomyozytenzellpopulation
US20210008172A1 (en)	2019-07-11	2021-01-14	Opko Biologics Ltd.	Long-acting igf-1 or igf-1 variants and methods of producing same
US20250179430A1 (en) *	2022-07-05	2025-06-05	Terasaki Institute For Biomedical Innovation	Cell growth supplements using dairy-based materials

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US408518A (en) *		1889-08-06		Stilt
US4196167A (en) *	1978-12-26	1980-04-01	California Medical Developments, Inc.	Drug detection device
WO1985000831A1 (en) *	1983-08-10	1985-02-28	Amgen	Microbial expression of insulin-like growth factor
US4745179A (en) *	1984-04-02	1988-05-17	Fujisawa Pharmaceutical Co., Ltd.	59 Valine insulin-like growth factor I and process for production thereof
SE8403479L (sv) *	1984-06-29	1986-01-29	Ssab Svenskt Stal Ab	Sett att framstella profilerade stenger
ATE81779T1 (de) *	1985-08-22	1992-11-15	Gropep Pty Ltd	Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren.
SE8505920D0 (sv) *	1985-12-13	1985-12-13	Kabigen Ab	New protein and its use
US4876242A (en) *	1987-09-21	1989-10-24	Merck & Co., Inc.	Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
CA2007886A1 (en) *	1989-01-17	1990-07-17	Marvin L. Bayne	Human insulin-like growth factor analogs with reduced binding to 28 k igf binding proteins and their production in yeast

1988
- 1988-12-20 AT AT89900786T patent/ATE116335T1/de not_active IP Right Cessation
- 1988-12-20 WO PCT/AU1988/000485 patent/WO1989005822A1/en not_active Ceased
- 1988-12-20 DE DE3852636T patent/DE3852636T2/de not_active Expired - Lifetime
- 1988-12-20 US US07/408,518 patent/US5164370A/en not_active Expired - Lifetime
- 1988-12-20 JP JP1500684A patent/JP2507106B2/ja not_active Expired - Lifetime
- 1988-12-20 EP EP89900786A patent/EP0346429B1/de not_active Expired - Lifetime
- 1988-12-21 CA CA000586713A patent/CA1341204C/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JPH02504279A (ja)	1990-12-06
EP0346429A1 (de)	1989-12-20
DE3852636T2 (de)	1995-05-04
EP0346429B1 (de)	1994-12-28
JP2507106B2 (ja)	1996-06-12
AU612776B2 (en)	1991-07-18
WO1989005822A1 (en)	1989-06-29
US5164370A (en)	1992-11-17
CA1341204C (en)	2001-03-13
EP0346429A4 (en)	1990-10-10
AU2900989A (en)	1989-07-19
DE3852636D1 (de)	1995-02-09

Legal Events

Date	Code	Title	Description
1995-07-15	UEP	Publication of translation of european patent specification
1999-09-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE116335T1 (de)	1995-01-15	Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
AU6286986A (en)	1987-03-10	Peptide analogues of mammalian insulin-like growth factor-1
DE69016655D1 (de)	1995-03-16	Biologisch aktive polypeptide, die auf transformierten wachstumsfaktor-beta-sequenzen basieren.
ATE121755T1 (de)	1995-05-15	Deletionsanaloga von magaininpeptiden.
ATE213499T1 (de)	2002-03-15	Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
ATE377026T1 (de)	2007-11-15	Behandlung von fettleibigkeit
ATE146188T1 (de)	1996-12-15	Substituierungsanaloge von magaininpeptiden
MX167236B (es)	1993-03-11	Peptidos sinteticos de timosina -1 y metodo para su obtencion
ES2135398T3 (es)	1999-11-01	Compuesto y composiciones de inhibicion de la resorcion osea.
MY103251A (en)	1993-05-29	Biologically active molecules
AR004497A1 (es)	1998-12-16	Un análogo hexapéptido cíclico de somatostatina, procedimiento para prepararlos y las composiciones farmacéuticas que los contienen y el uso de dicho hexapéptido para la preparación de una composición farmacéutica.
DE69102069D1 (de)	1994-06-23	5-aminosalicylsäurederivate zur therapie chronisch entzündlicher baucherkrankungen.
BR8807658A (pt)	1990-08-07	Peptideos tendo homologia estrutural, formulacao antigena farmaceutica e processo para alterar as caracteristicas de um vertebrado
KR890700673A (ko)	1989-04-26	돼지 성장호르몬 아날로그
NO901558D0 (no)	1990-04-05	Vasoaktive peptider.
GB1119353A (en)	1968-07-10	Peptides having an adrenocorticotropic hormone action and process for their manufacture
AR247473A1 (es)	1995-01-31	Una composicion que produce una respuesta lactogenica o crecimiento en ganado bovino, excluidas todas sus aplicaciones terapeuticas
JPS5750948A (en)	1982-03-25	Insulin analog and preparation
RU97117935A (ru)	1999-07-10	Свойства пептидов, стимулирующих рост
DK661888A (da)	1989-01-27	Biologisk aktive molekyler
TH21046B (th)	2006-12-08	ฮอร์โมนเทียมเพื่อการเจริญเติบโตของหมู
JPS5791965A (en)	1982-06-08	Preparation of polypeptide